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Abstract
Recent studies in cystic fibrosis (CF) transmembrane regulator (CFTR) mutations and function have shed light on its involvement in disease progression. The extent 
of cell and tissue distribution of CFTR facilitates systemic dysfunction of ion transport in patients carrying a mutation in CFTR, however, its incidences as co-
founding risk factor to develop other diseases is not well studied. In this review we differentiate the dysfunctions driven by CFTR mutations in cell of the immune 
system and their role in CF progression and examine the types of medical treatments available to patients up to date.
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Introduction
Identification of mutations associated to Cystic Fibrosis (CF) 
was initially searched in lung cell, epithelia, mucus goblet cells, etc. 
However, recently it has become more obvious that cystic fibrosis 
transmembrane regulator (CFTR) mutation on immune cells produces 
dysregulation in the lung even before infections occur. In this review 
we summarized how affects immune cells response and how it has 
changed the treatments of CF.
Types of mutations of the cystic fibrosis transmembrane 
regulator
Cystic Fibrosis is an autosomal life threatening recessively inherited 
human disease assigned to the Mendelian Inherited disease in Man 
(MIM) number 219700. Clinical manifestations of the CF pathology 
are mainly associated to the impairing functions of gastrointestinal 
and respiratory tracts. Pathological characteristic of CF are commonly 
associated to exocrine pancreatic insufficiency, recurrent lung 
infections, intestinal manifestations and “salty” sweat. Also secondary 
pathologies such as liver disease, pancreatitis, and diabetes were 
observed in some patients [1]. 
The frequency of CF is in average 1 in 2,500-3,000 live births, 
meaning about 80,000 people worldwide and about 1,000 new cases 
of CF are diagnosed yearly. However, the probability of CF frequency 
is related to the geographic distribution and ethnicity. In Europe, 
the highest prevalence of CF is observed in Ireland (1/1,700) and the 
lowest in Finland (1/7,700). In the United States, the birth frequency 
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affected of CF is 1/2,500 births for Caucasians of Northern European 
descent, 1/3,500 for Hispanics, 1/15,100 for Africans and 1/35,000 for 
Asians. The life expectancy of CF patients is increasing based on novel 
therapeutic strategies and novel technologies. During the 80`s the 
patient average life expectancy was about 14 years, increased during 
the 90`s to around 18 years and today is in between 30 to 40 years 
old [2]. However, there are huge differences between the patient’s life 
expectancies in developed and undeveloped countries. 
The CF disorder is produced by mutations in a gene located in the 
human long arm of chromosome 7 (specifically 7q31.2) and assigned 
to abnormal CFTR protein mainly expressed in secretory epithelial 
cells. The CFTR is mainly located in cytosol (about 85%), meanwhile 
the other 15% belongs to the lumen and ER membrane. From the 
structural point of view, the CFTR possess three different types of 
domains: two membrane spanning domains, one regulator, and two 
nucleotide binding domains for cAMP and cGMP [3,4]. Up today, 
1997 mutations have been identified in the CFTR gene reported by the 
Cystic Fibrosis Data Base (http://www.genet.sickkids.on.ca/CFTR/). 
The large amounts of CFTR mutations are related to sequence and/
or promoter variation, missense and non-sense, sequence variation, 
frame in/del, large in/del, splicing and unidentified types involving 
mutations in different exons and/or introns. From physiological and 
therapeutic point of view, the mutations were identified roughly into 
six classes [5] (Table 1).
The types 1 to 3 are most prevalent mutations and related to 
pancreatic insufficiency, meanwhile types 4 to 6 are not. Particularly, 
class 2 is the dominant CF-mutation in Caucasians affecting 86% CF 
alleles. The class 2 mutation is based on the absence of three nucleotides 
coding for phenylalanine amino acid in the 508 position of the encoded 
protein named F508del [1]. Also, the frequency of F508del is variable 
according to the population. For example, F508del is affecting the 82% 
of CF patients in Denmark and 32% in Turkey [5]. 
CFTR function
The basis of CF pathology is linked directly to malfunction of the 
Cystic Fibrosis Transmembrane Regulator (CFTR) protein associated 
to the trans-epithelial chlorine conduction, but also implicated in 
the transport of other molecules through the membrane [6,7]. The 
physiological role of CFTR is complex because intervenes in the 
regulation of other channels like Renal Outer Medullary potassium 
channel (ROMK K1+), Epithelial sodium (Na1+) Channel (ENaC), 
Outwardly Rectifying Cl1- channel (ORCC), and Cl1-/HCO31- exchanger 
[8-10]. The CFTR protein is a channel member of the ATP-binding 
cassette superfamily (ABC transporters) commonly described as ATP 
hydrolyzing proteins able to transport different molecules through 
cellular membranes against concentration gradients [11]. The CFTR 
transporter is classified as ABCC7 found in almost any form of life 
but with different ion permeability [12]. Also, the CFTR transporter 
in humans is naturally expressed in many types of cells like lung 
microvasculature and epithelia, pancreas, liver, heart myocytes, 
brain (hypothalamus), colon. The CFTR gene sequence is over 300 
Kb pairs containing 27 exons and coding for a protein of 1480 base 
pairs with approximately 180 kD MW containing approximately 7% of 
glycosylated residues (galactose, fucose and sialic acid). 
CFTR structure
From structural point of view, the CFTR protein is arranged in 7 
domains with two amino and carboxyl termini located in the cytoplasm, 
two membrane-spanning domains containing six membrane-spanning 
segments, a regulatory domain and two nucleotide binding domains 
named NBD1 and NBD2 (Figure 1). 
The structure of the two membrane domains is composed of six 
helixes each represent the 25% of the protein with 19% on membrane 
and 4% on surface. Besides, the two membrane domains are the 
gateway and control of chloride flux [13]. The two cytoplasmic NBDs 
are the regulatory domains involving the ATP binding and hydrolysis 
sites that induce conformational changes and dimerization [14]. The 
structural changes of the NBD dimer regulate the ion fluxes trough the 
gateway. The NDBs domains are rich in phosphorylation sites, which 
resemble protein kinases [14]. 
Regulation of the CFTR 
The mechanism of CFTR regulation is very complex (Figure 1) 
and involves different regulatory levels such as phosphorylation and 
dephosphorylation, posttranslational modifications, e.g. glycosylation, 
to the interaction with membrane and cytoplasmic proteins, and 
check point of appropriate CFTR structure. The phosphorylation/
dephosphorylation mechanisms on NBD domains of the CFTR are 
required to activate and deactivate the chloride ion channel a cAMP-
dependent manner [15]. The phosphorylation of CFTR by PKA 
is catalyzed by the subunit PKA-cat and regulated by the subunit 
PRKAR2A through the villin-2 protein (also known as Ezrin) who 
anchors PKA-cat. Villin-2 interacts with the NBD domain of CFTR 
mediated by the regulatory protein E3KARP (also named as NHERF-2) 
containing a PDZ binding motif. The PDZ motif of E3KARP possess 
high affinity for the PDZ counterpart motif located at the carboxylate 
terminus of NDB domain and also Annexin II protein complex, involved 
in the interaction to enhance the phosphorylation of CFTR [16]. On the 
other side, activation of PKA mediated by adenosine also induced the 
activity of phosphodiesterase 4D (PDE4D) catalyzing the conversion of 
cAMP into AMP. The AMP product activates 5‘AMP activated protein 
kinase (AMPK) acting a negative effector by phosphorylating the NDB 
of CFTR and reducing the chlorine ion transport [17]. Also, protein 
phosphatases type II (PP2A and PP2C) dephophorylates CFTR causing 
inhibition of ion transport [18]. Besides, other protein complexes like 
the synatosomal-associated 23 kDa protein (known as SNAP-23)-
syntaxin 1A interfere sterically with the CFTR transporter reducing the 
chloride ion transport [19].
EBP50, another protein with PDZ binding domain, is the protein 
Class Mutation Cellular and/or molecular phenotype
I Trp1282X, and Gly542X Absent CFTR synthesis due to non-sense mutations, or frame shift mutations, or abnormal mRNA splicing.
II Phe508del Defective intracellular processing of CFTR with less than normal amounts of CFTR protein at the apical plasma membrane.
III Gly551Asp Defective regulation of CFTR channels at the apical plasma membrane.
IV Arg117His Defective transport of anions through CFTR channels at the apical plasma membrane.
V 3849+10KbC>T Reduced production or processing of normal CFTR.
VI Gln1412X Altered apical membrane residence time of CFTR channels with truncated c-termini.
Table 1. Classification and description of cystic fibrosis mutations.
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bridge between Beta-2 adrenergic receptor (ADRB2) and CFTR. 
However, the complex formation with the beta-2 adrenergic receptor 
is inhibited when the PKA phosphorylates the CFTR. The ADRB2 is 
a receptor for the binding of epinephrine and linked to the calcium 
ion channel, which is functional for smooth muscle relaxation 
and bronchodilation [20]. Another way to inhibit the CFTR is by 
suppressing the activity of PKA and adenylate cyclases depressing the 
cAMP in the cell by members of G-protein -I family cascade [21].
The regulation of the CFTR function involves also the interaction of 
the transporter with cytoplasmic proteins like NHERF-1 and regulating 
the ion flux at the gateway [22]. In addition, the endoplasmatic 
reticulum (ER) is working as “custom” of the CFTR transporter 
checking proper protein folding and glycosilation. Proteolysis of 
abnormal CFTR transporter was suggested by tagging the protein with 
an “adaptor ligase” activating the ubiquitin - proteasome degradative 
pathway associated to ER named as ERAD [23,24].
On the other hand, CFTR regulation is not only made in the cell 
cytoplasm but also in the cell membrane. CFTR was phosphorylated 
by Protein Kinase C-ε (epsilon) in order to stabilize the transporter 
in the membrane and also to prime the PKA. However, the PKC-ε 
is part of the protein complex pathway involving soluble carrier 
family 9 (member 3 regulator 1), guanine nucleotide binding protein 
-polyppetide2-like 1 [25,26].
CFTR mutations on inflammatory cells
It is thought that CF is an epithelia based disease; however CFTR 
dysfunction of immune cells plays a causal role in lung infection 
as CFTR mutations predisposes to Th2 bias that differentiates CF 
immune response from the rest of the lung diseases, and this precedes 
lung infections (Figure 2). In this review we will focus on the changes 
produced by CFTR mutations on immune cells [27,28].
Lymphocytes 
In order to achieve homeostasis after an inflammatory process has 
been initiated in response to cytokine stimulation, T helper’s naïve 
(Th0) cells are differentiated along Th1/Th2 and Th17/ T regulatory 
(Treg) lineages, which suppress the inflammation. Recently was shown 
that Tregs from patients with CF, or from knock out CFTR mice 
(CFTR / ), are impaired in suppressing conventional T effector cells, an 
 
Figure 1. Signaling pathways involved in CFTR regulation. Beta-2 adrenergic receptor (ADRB2), phosphatases type II (PP2A), Protein Kinases A (PKA), subunit PRKAR2A, Protein 
Kinases C (PKC), mitogen activated protein kinases (MAPKs) receptor for the binding of epinephrine (ADRB2), syntaxin 1A (STX1A), Phosphatidil inositol 3 kinase (PI3K). Nuclear 
Factor-κ B (NF-κ B) repressor (GSK3β), nuclear factor erythroid 2–related factor 2 (Nrf2), Toll like receptor 4 (TLR4), lipopolysaccharide (LPS), macrophage inducible protein-2 (MIP-2) 
by p38. Macrophage inducible protein-2 (MIP-2), Tumor necrosis factor α.  Macrophage metallo elastase 12 (MMP12), butyrate dehydrogenase type-2 (BDH2), iron carrier protein NGAL, 
heme oxygenase 1 (HO 1), β epithelial Na+ channel transgenic mouse (ENaC). Pointed arrows means activation and bold arrows inhibition. 
Figure 2. Schematic representation of lung immune response biases. Chronic obstructive 
pulmonary disease (COPD). Cystic fibrosis (CF).
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effect that was enhanced by P. aeruginosa infection. The loss of Tregs 
in CF affected memory, but not naïve, Tregs and manifested gradually 
with disease progression, confirmed by a positive association between 
lung function, measured by forced expiratory volume (FEV1%), and 
number of Tregs present in peripheral blood of CF patients [29,30]. 
Murine model of CF confirmed impaired Tregs down regulation 
of Th2 cells; CFTR-/- mice had enhanced intracellular Ca2+ flux in 
response to T cell receptor (TCR) activation on T effectors cells, 
higher interleukin (IL) 4, IL-13, IgE and IgG1, this prominent Th2 
bias correlated with higher nuclear NFAT level than their wild type 
control littermates (CFTR+/+). There was also an impaired inactivation 
of these cells by Tregs and defective Th1 response, indicating the CFTR 
importance to maintain the Th1/Th2 balance [30-32].
Th2 bias assessed in CF patients preceded the P. aeruginosa 
infection in a study conducted in 75 subjects, which proved a positive 
association among secretion of IL-5 with number of neutrophils in 
broncho-alveolar lavage (BAL) of CF subjects. There was a significant 
association among computed tomography changes and cytokines and 
chemokines assessed for Th2 bias (IL 5, IL 13, TARC/CCL17) and Th17 
(IL 17A, IL 6, IL 1β, IL 8) [33]. However, IL-13 seems to play a greater 
role then IL-4 in CF since lung parenchyma leukocytes produce high 
IL-13, IL-10 and RANTES levels and weakly IL-17, when exposed to 
Pseudomonas sp. 
The signaling path that determines Th2 bias includes the purinergic 
receptor (P2Y2) which senses ATP level secreted in a CFTR dependent 
manner in the first stage of inflammation upon infection (Figure 3) 
[34,35]. Upon viral infections knockout mice in P2Y2 had increased 
IL-6, reduced ATP, IL-12, and CD4+, CD8+ T cells and dendritic cell, 
with defective viral clearance and predominant Th2 bias but normal 
levels of IP10 and MIP-3 as represented in Figure 3 [35].
In addition to Th2 bias, the binding of IL-13 to its receptors on Th17 
cells down regulates IL-17A production (Figure 3) and its neutralization 
is necessary for significant IL-17 augmentation, this increase was a 
lesser amount with IFN-γ or IL-4 neutralization [27,28]. Consequently, 
T cells specific for Pseudomonas aeruginosa and Aspergillus fumigatus, 
obtained from patients with CF, displayed significantly higher IL 5 
and IL 17A mRNA expression and TARC/CCL17 in patients that 
developed P. aeruginosa infection within 24 months. High expression 
of these cytokines/chemokines in CF airways preceded infection with 
P. aeruginosa demonstrating an intrinsic predisposition of Th0 cells to 
differentiate to Th17 phenotype although they had normal capacity for 
Th1 and Treg differentiation [33,36,37]. 
Th17, IL-17+ neutrophils, γδT and natural killer T cells (NKT) are 
increased in newly diagnosed CF subjects with BAL fluid neutrophilia 
[38]. Th17 cells from CF subjects had an antigen-specific response 
rather than a merely nonspecific mitogen-induced IL-17 release. 
Within the CD4+IL-17+ population there were some expressing IL-22 
with a higher proportion of CD45RO+TCRαβ+ cells compared with 
Figure 3. Schematic representation of immune cross-talk among cells CFTR deficient. Cells represented are Macrophages (Macs), T helpers 2 (Th2), T regulatory (Treg) and Th17, 
neutrophils (Neut), mediators are Interleukins (IL), nitric oxide (NO), interferon gamma (INFγ), interferon gamma inducible protein 10 (IP10), chemokine receptor 3 (CXCR3), leukotriene 
B4 (leuk4), hepoxilin A3, macrophage inducible proteins (MIP) 1, 2, 3. Autophagy protein p62, Scaffold protein Ksr1, heat shock protein 90 (Hsp90), nitrogen oxide synthase (iNOS), T cell 
receptor (TCR), secretion proteins (S100A8, S100A9 and S100A12), receptor for advanced glycation end products (RAGE). Mucine 5 A (MUC5A), indole-amine 2,3 dioxygenase (IDO). 
Th2 bias includes the purinergic receptor (P2Y2). Pointed arrows means activation and bold arrows inhibition.
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IL-22- cells, suggesting a role for IL-22 in maturation of the adaptive 
response to develop memory T-cell fraction [27]. The mechanism of 
Th17 production involves indole-amine 2,3 dioxygenase (IDO), since 
in murine and human CF dysfunctional IDO activity correlated with 
imbalanced Th17/Treg cell responses to Aspergillus fumigatus, that was 
restored by genetic recue of IDO production as represented in Figures 
1 and 2 [39].
Tregs are essential to maintain immune system homeostasis by 
suppresing T effector cells harnessing tissue destruction; in healthy 
humans, fungus specific CD4+CD25+CD127 Foxp3+ Treg are strongly 
expanded in peripheral blood and possess phenotypic, epigenetic and 
functional features of thymus derived Treg. However, for Aspergillus 
sp., the strong Treg response contrasts with minimal conventional T cell 
memory, indicating selective Treg expansion as an effective mechanism 
to prevent inappropriate immune activation in healthy individuals. By 
contrast, in subjects with Aspergillus sp. allergies, specific Th2 cells were 
strongly expanded despite the presence of specific Treg [40]. Upon P. 
aeruginosa infection CFTR-/- mice had reduced Treg count, while in CF 
patients there was impaired Treg suppression of Th2 inflammation, 
indicating the same impairment that underlay Aspergillus sp. infection 
[30]. 
It has emerged autoimmunity particularly overt in cystic fibrosis 
mice lacking invariant natural killer T (iNKT) cells which play a role 
to control autoimmune diseases triggered by a ceramide mediated 
induction of cell death in CF, and although suppression of the 
autoimmune response by iNKT cells is beneficial, IL 17+ iNKT cells 
attract macrophages and neutrophils to CF lungs resulting in chronic 
inflammation. Genetic deletion of iNKT cells in cystic fibrosis mice 
prevents inflammation in their lungs [41].
In summary, CFTR deficiency is highly disruptive of T cells function 
promoting an exaggerated Th2 response, reduced Treg population and 
enhanced Th17 response, this increases neutrophils recruited by IL-17 
to the lung, which are a major cause of alveoli destruction associated 
with lung decay in CF. 
Macrophages 
Cystic fibrosis patients are susceptible to infections of opportunistic 
extracellular or intracellular pathogens, the appropriate immune 
response is different for each type of infection and the capacity to 
resolve it favorably depends on the CFTR impairment of the immune 
cell type involved. CF patients with mucoid P. aeruginosa chronic 
infections have a positive correlation between lung function and 
interferon IFN-γ produced by CFTR-/- peripheral blood mononuclear 
cells. In contrast, IL 17A levels tended to correlate negatively with lung 
function [42]. IFN γ induces phagocytosis binding autophagy protein 
p62, which promotes the double membrane vacuolization around 
the infecting bacteria increasing traffick to the lysosomes (Assani et 
al., 2014). IFN γ also up regulates monocytes the chemo-attractant 
protein 1 (MIP-1), tumor necrosis factor α (TNF α) and IL 6 production 
and down regulates IL 10 expression in infected macrophages [42]. 
Macrophages with CFTR depletion from membrane lipids raft, 
caused by second hand smoke, lypopolysaccharide (LPS) or alginate 
produced by P. aeruginosa, or mutations, have inhibited their phagocytic 
capacity [44,45]. CFTR-/- macrophages exhibit aberrant acidification 
of phagolysosomes and do not kill internalized microorganisms as 
effectively as wild-type cells do [46].
Bacterial LPS produces uncontrolled toll like receptor 4 (TLR4) 
signals through phosphatidil inositol 3 kinase (PI3K), activating Akt, 
which inactivates the Nuclear Factor-κ B (NF-κ B) repressor (GSK3β) 
inducing nuclear transcriptions factor (NF-κ B), p38 and mitogen 
activated protein kinases (MAPKs) activity transcribing TNF-α, IL-
6,IL-8 and macrophage inducible protein-2 (MIP-2) and repressing 
of scaffold protein CAV1. CFTR-/- macrophages have upregulated 
phospholipase A2α (PLA2α) activity and IL-6 secretion, which is lethal 
upon P. aeruginosa infection. IL-6 was decreased in PLA2α-/- mice 
without affecting IL-1β, or TNF-α [47-49].
The uncontrolled TLR4 signaling is due to high microRNA 199a 5p 
levels, which are PI3K/AKT dependent, However, PI3K/Akt activation 
does not regulate phagocytosis; rather AKT/miR 199a 5p/CAV1 
pathway promotes migration of monocytes and neutrophils responsible 
of hyperinflammation, tissue damage and lung decay [49,50]. 
LPS triggers inflammatory response in the reticulum (Figure 
1) down regulating the short chain butyrate dehydrogenase type-2 
protein and up-regulating the expression of iron carrier protein NGAL 
and stress inducible heme degrading enzyme heme oxygenase 1 (HO-
1) leading to iron liberation from macrophages [51]. LPS and INF-γ 
improves macrophages killing of P. aeruginosa inducing scaffold protein 
Ksr1 (a ceramide-activated, serine-threonine kinase) that recruits heat 
shock protein 90 (Hsp90) and nitrogen oxide (NO) synthase (iNOS) 
to form a membrane complex that produces NO and nitric peroxide 
essential for bacterial clearance, as genetic deletion of Ksr1 impairs 
bacterial clearing and causes mouse lethality to P. aeruginosa infection 
[52-54]. 
Mycobacterium abscessus is an intracellular macrophage pathogen 
that has emerged as a risk factor for CF patients. M. abscessus infection is 
accompanied by increased HO 1 precursor of billirubin and billiverdin 
regulators of reactive oxygen species (ROS). The HO-1 is induced by 
p38 MAPK dependent, as p38 inhibitors suppressed HO 1 and inhibited 
M. abscessus growth inside macrophages. Furthermore, inhibiting 
HO 1 using HO 1 siRNA or the HO 1 upstream signaling molecule, 
nuclear factor erythroid 2–related factor 2 (Nrf2), with siRNA results in 
similar inhibition of M. abscessus [55]. Nrf2 regulates a cytoprotective 
response to counteract oxidative stress–induced essential for clearance 
of intracellular pathogens like M. abscessus but a fine equilibrium has 
to be maintained since decrease in Nrf2 signaling is associated with 
the progression of diseases driven by oxidative stress response. This 
indicates that targeting Nrf2 can improve innate antibacterial defenses, 
and restore corticosteroid responses in chronic lung diseases [56]. 
Viral infection of mice heterozygous in CFTR mutation (CFTR 
+/-) showed that TGF β dependent production of IL 6 by macrophages 
late in infection prevents acute lung injury from influenza A virus 
infection. This effect in CFTR+/- mice was associated with post-infection 
production of TGF β with higher IL 6 and alveolar macrophages at 6 
days post infection that did not occur in Wt mice. Neutralization of 
β-TGF reduced IL-6 secretion but IL 6 neutralization did not affect 
BAL macrophages and neutrophils numbers, rather it attenuated the 
CXCL 1/KC response in both strains, and reduced IFN γ production 
in WT mice. All this is indicating that IL-6 is involved in activation 
of macrophages rather than recruitment, and the IFN γ/IP10/MMP12 
pathway is essential for acute lung injury as recently the relevance of 
MMP12 in lung injury of CF patients was assessed with the β epithelial 
Na1+ channel transgenic mouse (βENaC Tg) that presents dehydrated 
airway and increased secretion of activated MMP12 (Figure 3). 
They also showed elevated MMP12 activity on the surface of airway 
macrophages in BAL from βENaC Tg mice and patients with CF. 
Further, they report MMP12 polymorphism associated with severity 
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of CF, indicating a new mechanism of emphysema triggered by ionic 
dysregulation rather than cigarette smoke exposure [57-59].
In summary, this data suggest that macrophages may be driving 
lung decay in CF through activation of MMP12. 
Neutrophils 
Patients with CF display exaggerated neutrophilic responses 
to pathogens and their neutrophils have an impaired capacity to 
undergo apoptosis, even prior to migration to the lung, as shown for 
Pseudomonas colonized F508 homozygote CF blood neutrophils. The 
blood inflammatory markers interleukin 1beta (IL 1β), C reactive protein 
(CRP) and myeloperoxidase (MPO), are elevated during recruitment 
of neutrophils to the lung [60].
Neutrophils roll in the blood stream and adhere to the vasculature 
of the injured site where the cytokines and chemokine are being 
produced, after chemotaxis they egress to the lung epithelia. Neutrophils 
carryng CFTR mutation G551D have significantly higher expression of 
active adhesion molecule CD11b and of CD63 on monocytes, ex vivo 
exposure to ivacaftor of blood cells from G551D, but not F508del and 
healthy subjects, resulted in changes in CXCR2 and CD16 expression 
on neutrophils [61].
Neutrophils recruitment to the lung is dependent of IL-17, 
CXCL1/KC and IL-1 production [33,62]. Epithelia cells that have 
been injured signal through hepoxilin A3, a chemotactic eicosanoid 
that mediate the transepithelial passage of neutrophils, in response 
to infection (Figure 3). Neutrophil derived leukotriene B4 signaling is 
generated by migrated neutrophils augmenting the initial hepoxilin 
A3 and collectively coordinate an effective neutrophilic transepithelial 
migratory response [63].
Decreased IL 17 and the homolog to IL 1 (IL 8 in mice) results from 
the deficiency of calcium activated chloride channel regulators (CLCA3-
/-) with reduced neutrophilic infiltration into the bronchoalveolar 
space during bacterial infection, compared to wild type mice [64]. 
Glycosaminoglycans influence the chemokine profile of the CF lung 
by binding IL-8 and protecting it from proteolytic degradation. IL-8 
is maintained in an active state by this glycan interaction increasing 
neutrophil infiltration into the lungs [65]. IL-8 recruits and activates 
neutrophils through G-couple chemokine receptor (CXCR1), this is 
regulated through elastase cleavage of the receptor mediated by PAR-2, 
which co-localizes with CXCR1.
Neutrophils egress from the microvasculature is mediated by VAP-
1/SSAO, an endothelial bound adhesion molecule with amine oxidase 
activity. Adherence is induced by CXCL1/KC and inhibition of VAP 1/
SSAO also dampenes migration of neutrophils to the lungs in response 
to LPS [66]. Upon arrival to the lung neutrophils interact with epithelial 
cells through secretion of proteins S100A8, S100A9 and S100A12 
which binds TLR4 and the receptor for advanced glycation end-
products (RAGE) stimulating mucin production from epithelial cells 
(Figure 3) [67]. C reactive protein (CRP) generated in inflamed tissues 
inhibits neutrophil apoptosis via a mechanism involving activation of 
FccRIII (CD16) and PI3K. Inhibitor of PI3K, LY294002, increased CF 
neutrophils apoptosis in 50%, similar to normal patients’ neutrophil 
apoptosis [68]. In addition to prolonged life span, that impairs 
inflammation resolution, neutrophils carrying CFTR mutations have 
significantly higher expression of active CD11b and compromised 
phagocytosis, which predispose CF lungs to infection [61,69].
In the tissue, neutrophils arrest P. aeruginosa growth by 
chemotactic effect undergoing a respiratory burst following C3b and 
Fc receptor activation with extracellular release of ROS such as O2-, 
H2O2 and NO, consuming large amounts of O2 forcing the bacteria to 
enter into anaerobic metabolism [70-72]. In addition, hypochlorus acid 
produced by this mechanism is reduced by MPO oxidizing glutathione 
to glutathione sulfamides [73]. 
CF blood neutrophils release less granule containing MPO, 
neutrophil elastase (NE) and extracellular DNA compared with 
control patients and this is associated with reduced activity of the 
low molecular weight GTP-binding protein Rab27a due to higher 
intracellular Cl-, lower Mg2+ and reduced degranulation and killing 
ability [74]. Degranulation of neutrophils by gram-negative bacteria is 
mediated by galectin-9 (Gal 9) interaction with T cell immunoglobulin 
and mucin domain containing molecule 3 (TIM-3). TIM 3/Gal 9 
signaling modulates cytosolic Ca2+ levels and enhaces NADPH activity 
that is essential for ROS production [75].
Over all, the reduced apoptosis, degranulation and killing ability 
caused by the ionic imbalance of CFTR mutation together with 
increased adhesiveness leads to neutrophilia in CF lungs  (Figure 3) 
that negatively correlates with their FEV1 [60]. 
CF Infections 
Colonization by bacteria may synergize, amplify, or trigger 
pathways of tissue damage; the most common infection in cystic 
fibrosis patient is P. aeruginosa. However, many other opportunistic 
pathogens are also able to colonize the lung of these patients, infections 
that ultimately leads to respiratory failure. 
P. aeruginosa infection
The growth rate of P. aeruginosa within CF lungs inversely 
correlates to the concentration of neutrophils surrounding the bacteria. 
A growth limiting effect on P. aeruginosa by neutrophils was also 
observed in vitro, where this limitation was alleviated in the presence of 
the alternative electron acceptor nitrate. The finding that P. aeruginosa 
growth patterns correlate with the number of surrounding neutrophils 
points to a bacteriostatic effect by neutrophils via their strong O2 
consumption and release of ROS upon activation, which slows the 
growth of P. aeruginosa in infected CF lungs [72]. Never the less P. 
aeruginosa has the ability to circumvent this bactericidal mechanism 
producing kynurenine an oxygen peroxide and superoxide scavenger 
that has no effect on phagocytosis or oxygen consumption by activated 
neutrophils but rather in their phagosome [76].
Burkholderia cenocepacia infections
Burkholderia cenocepacia infects patients with CF within their 
macrophages in membrane vacuoles that preclude fusion with the 
lysosome [77-80]. B. cepacia complex co-infects with P. aeruginosa 
reducing its biofilm capacity. B. cenocepacia and B. multivorans express 
mucinases that utilize mucin as carbon source and fermentation 
rather than anaerobic respiration to obtain energy [81]. Burkholderia 
pseudomallei is the causative agent of melioidosis characterized by 
pneumonia and fatal septicemia and a strong risk factors of mortality 
in CF [82]. 
Mycobacterium abscessus infections
Mycobacterium abscessus is a rapidly growing mycobacterial 
species that infects macrophages, and is an important pathogen in 
patients with CF [55]. Genome analysis of this bacterium showed its 
metabolic pathways typically found in environmental microorganisms 
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that come into contact with soil, plants, and aquatic environments but 
also contains several genes that are characteristically found only in 
pathogenic bacteria. One of them is MAB_0555, encoding a putative 
phospholipase C (PLC) that is absent from most other rapidly growing 
mycobacteria, including Mycobacterium chelonae and Mycobacterium 
smegmatis. PLC is highly cytotoxic to mouse macrophages, presumably 
due to hydrolysis of membrane phospholipids. Using an M. abscessus 
PLC knockout mutant was shown that loss of PLC activity is deleterious 
to M. abscessus intracellular survival in amoebae [83]. This ability to 
survive intracelullary in macrophages and neutrophils initiate the 
formation of cords that when released from apoptotic macrophages or 
neutrophil become too large to be phagocytized. Cords initiated in the 
vasculature enter the central nervous system producing abscesses in the 
brain of CF patients [84]. Aspergillus spp. are present in the airways of 
20 40% of CF patients and are of unclear clinical significance [31]. 
In addition to lung infections, patients with CF has reduced 
intestinal richness with decreased levels of Eubacterium rectale, 
Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium 
adolescentis, Bifidobacterium catenulatum, and Faecalibacterium 
prausnitzii and increased levels of inflammation shown by higher 
fecal levels of calprotectin and rectal nitric oxide [85]. Stimulating 
the growth of species involved in immunity development, such as 
Bifidobacterium species, Sutturella wadsworthia, and Clostridium 
cluster XIVa organisms, and at the same time increased the production 
of butyrate and propionate seems to be possible to restore Th1 bias and 
INF-γ levels that improves bacterial clearance [86]. 
Treatments of CF disease
Antibiotics resistance of pathogens infecting CF patients is a 
hallmark of the disease. The use of phytochemicals to enhance bacterial 
susceptibility to antibiotic, like zingerone (active components from 
ginger) seem to increase the P. aeruginosa sensitivity to antibiotics by 
reducing its cell surface hydrophobicity, alginate and LPS production, 
thus increasing its phagocytic susceptibility by macrophages decreasing 
TNF-α and MIP-2 produced by them [87]. 
In addition, alterations of the intestinal microbiota impacts 
the systemic immune response, reports suggest that dietary acidic 
oligosaccharides can favor a Th1 immune response, restoring INF-α 
level in the lung and bacterial clearance [86]. 
Antibiotics therapy
The chronic bacterial infection found in the airways is a recurrent 
problem in the CF disease, particularly susceptible to Pseudomonas 
aeruginosa, which is by far the most significant pathogen responsible of 
morbidity and mortality [88]. Repetitive and prolonged infections allow 
the selection of hyper mutated strains of P. aeruginosa with antibiotic 
multiresistance to conventional therapies and able to persist for years 
in most patients [89]. Once the strain converts to mucoid phenotype, 
an exacerbation of alginate secretion is produced and thereby the strain 
becomes extremely difficult to eradicate. In the biofilm architecture, the 
microorganisms are capable to survive even under aggressive antibiotic 
treatments [90]. Thus, an early “antibiotic eradication therapy” is highly 
recommended in CF [91,92]. Undoubtedly, appropriate therapies 
and strict use of multi-antibiotic doses are responsible of life-quality 
improvement and increased survival of CF patients. 
Nowadays, there is not a consensus among clinicians about the 
most adequate antibiotic treatment against P. aeruginosa [93]. Table 
2 summarizes the antimicrobial agents commonly use and their 
recommended doses [93]. Many factors are influencing the efficiency 
of drug therapies but not only based on the antibiotic therapeutic 
properties but also considering other factors like molecular properties 
of drugs (e.g. chemical structure, functional active groups, solubility, 
biodisponibility, target sites), the route of administration and 
importantly the formulation of therapeutic molecules.
Some microbial isolates from CF sputum were completely 
susceptible to antibiotics like: tobramycin, ceftazidime, colistin, 
imipenem, levofloxacin, and ciprofloxacin, and synergetic effects have 
been found with combination some of them [94]. The administration 
of inhaled antibiotics in addition to other antibiotics orally deliver in 
treatment for 3 weeks to 3 months has been used successfully [95]. A 
decrease in lung inflammation has been found in trial therapy with 
oral/inhaled antibiotic treatment in comparison with intravenous 
administration [96]. In fact, 3 months treatment with of high-doses 
of inhaled colistin combined with oral ciprofloxacin had produced the 
best therapeutic results in management of Pseudomonas aeruginosa 
infections [97].
Nano particles therapies
However, novel therapeutic alternatives are under intensive studies 
Family Antibiotic Administration route Number of administrations per day Dose per day (mg/kg)
Aminoglycosides Amikacin i.v. 2 30
Tobramycin i.v. 2 10
inhaled 1-2 150-300
Netilmicin i.v. 2 10
Betalactamics Aztreonam i.v. 4 150
i.v. continuously 100
Imipenem/cilastatin i.v. 3-4 50-100
Cephalosporins Cefepime i.v. 2-3 100-150
Ceftazidime i.v. 3-4 150-250
i.v. continuously 100-150
Quinolones Ciprofloxacin oral 2-3 30
Polymyxins Colistin inhaled 1-2 80-160
Carboxypenicillins Ticarcillin i.v. 4 500-750
Carbapenems Meropenem i.v. 3 60-120
i.v. continuously 60
i.v. = intravenous 
Table 2. Antibiotics dosages commonly used in the management of cystic fibrosis patients with Pseudomonas.
aeruginosa lung infections (modified from Döring et al., 2000).
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to increase the effectiveness of conventional antibiotics and to overcome 
the resistant mechanism of microbial pathogens. In this sense, novel 
strategies are focus on the antibiotic encapsulation in nano- and micro-
carriers to improve the antibiotic biodisponibility, and to provide a 
proper molecular control release profile under the therapeutic window, 
avoiding the use of high concentrations which results in undesirable 
hepatic- and nephro-toxicity side effects. Among them, quinolones and 
amikacin have been encapsulated in liposomal formulation or solid lipid 
nanoparticles for pulmonary delivery, improving the biodistribution 
of the antibiotics and the patients’ compliance [98]. Figure 4 shows 
images of amikacin loaded nanoparticles biodistribution in rats. 
However, the dynamic characteristics of liposomes and their intrinsic 
instability under different physicochemical environments do not allow 
predicting and determining the precise amount of delivered drug and 
their efficiency in the lungs. On the contrary, biopolymers are good 
alternative to make matrices for drug delivery since most of them are 
non-toxic, biodegradable, easily tailorable, and cheap. Also, biopolymer 
devices for drug delivery are advantageous since there are able make 
stable gel structures, can carry more than one therapeutic molecule, 
the amount of cargo/s can be very well-establish allowing to determine 
specific molecular kinetic release. For example, co-administration 
of quinolones and enzymes with complementary functions (such as 
alginate lyase or Dnase) encapsulated into biopolymer microspheres 
has been reported successful to decrease viscoelasticity of the purulent 
mucus and enhance the antibiotic efficiency [99,100]. The main 
advantage of combining antibiotics and hydrolytic enzymes are to 
increase not only the diffusivity of the antibiotic through the biofilms 
reaching the microbial cell surface more easily but also reducing the 
antibiotic dose. Also, the use of phytochemicals seems to enhance 
bacterial susceptibility to antibiotic and improve antibiofilm efficacy 
of ciprofloxacin against P. aeruginosa PAO1. Active components like 
zingerone (extracted from ginger) could increase the P. aeruginosa 
sensitivity to antibiotics by reducing its cell surface hydrophobicity 
and decreasing the alginate and LPS production. Consequently, there 
is an increase in its susceptibility to phagocytosis by macrophages 
decreasing the TNF-α and MIP-2 levels [86]. Other works reveal 
that extracts of garlic could act as anti-quorum sensing molecules, 
preventing biofilm formation, increasing the clearing of the infecting 
bacteria and potentiating the effect of tobramycin [101].
Microbiome maintenance 
A relatively new research field is focus on the study of the lung and 
gastrointestinal microbiome of CF patients. Both microbiotas seem 
to be intrinsically influenced in such a way that the development and 
maintenance of lung immunity and inflammation are related with the 
intestinal microorganisms [102]. It was observed a strong correlation 
between low species richness and poor lung function [103]. Studies 
revealed that microorganisms in the intestine will be playing an 
important function in regulating T helper cells, regulatory T cells and 
dendritic cells as well as Toll-like receptor expression in macrophage 
and dendritic cells, which are the key tools to combat bacterial 
infections [104,105]. 
Patients with CF have reduced intestinal richness with low levels 
of Eubacterium rectale, Bacteroides uniformis, Bacteroides vulgatus, 
Bifidobacterium adolescentis, Bifidobacterium catenulatum, and 
Faecalibacterium prausnitzii, and usually present a serious degree of 
inflammation which is reflected in the higher fecal levels of calprotectin 
and rectal nitric oxide [85]. 
An alternative to restore the balance of the microbiome is 
set by stimulation of the growth of species involved in immunity 
development, such as Bifidobacterium and Lactobacillus species, 
Sutturella wadsworthia, and Clostridium cluster XIVa organisms. 
Studies have demonstrated that prebiotics could stimulate the growth 
of bifidobacteria and lactobacilli, developing important immune-
modulating functions in Th1 response and T cell regulation. Short 
chain galacto-oligosaccharides and long-chain fructo-oligosaccharides 
are included in these non-digestible carbohydrates group. At the 
same time, prebiotics can be degraded by the natural intestinal flora 
to produce short-chain fatty acids (such as butyrate and propionate) 
which could reactivate the Th1 bias by increasing TNF-α levels that 
improves bacterial clearance [106].
Studies in mice models indicate that pretreatment with pectin-
derived acidic oligosaccharides may help to improve the incidence of P. 
aeruginosa pulmonary infection by increasing bacterial clearance with 
a shift in the Th1/Th2 balance toward a predominantly Th1 response [86]. 
Certainly, further studies will be necessary to explore the 
microbiome of different microbial communities in the airways and 
intestine of healthy and infected patients to elucidate the mechanisms 
involved in immunity and the relationship with strong antibiotics 
treatments [103].
Dietary supplements
Patients with CF need to follow a very strict diet according to the 
age and grade of illness, and therefore different nutrient requirements 
should be carefully monitored to guarantee a normal growth [107]. 
Due to the systemic mucus accumulated at different organs, clinical 
compliance is associated with malnutrition and poor absorption of 
foods in patients [108]. 
The Cystic Fibrosis Foundation highlights that patients treatment 
include the supplying of adequate calories, intake of sufficient vitamin 
D and K and specially incorporation of calcium enough to avoid 
pathologies like osteopenia and osteoporosis [109].  Table 3 shows the 
most relevant nutrients that patients need to take into account for a 
suitable nutrition. 
Figure 4. Gamma scintigraphy photographs of rats receiving amikacin loaded solid lipid 
nanoparticles (SLNs) (a) i.v. after 0.5 hour, (b) i.v. after 6 hours, (c) pulmonary after 0.5 
hour, and (d) pulmonary after 6 hours (Varshosaz et al., 2013).
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One of the main causes of malnutrition in patients is due to a 
pancreatic insufficiency (PI). When PI is present, an active nutritional 
management is started by the addition of pancreatic enzymes to 
the diet. Preferably, enzymes are encapsulated in microspheres or 
microtablets, which provide them protection against the enteric acidity 
and prevent their rapid inactivation [107]. However, the enzymatic 
activities released in the intestine are not very efficient as it should 
be required by the pathology. A complementary strategy is based on 
the ingestion of prebiotics has a positive impact in the restoration of 
a health microbiota at intestine and an enhancement of the systemic 
immune response is usually observed. Reports suggest that dietary 
acidic oligosaccharides can favor a Th1 immune response, restoring 
INF-α level in the lung and bacterial clearance [86].
Gene transfer
The main focus for the next generation of therapeutics is based 
on the concepts of metabolic engineering by reprogramming cell and 
tissue metabolism and correcting metabolic deficiencies by changes 
in the somatic cell genomes using gene delivery technologies. In the 
last decades, different attempts have been focus in the restoration 
of the defective human cystic fibrosis transmembrane conductance 
regulator. Some experiments in transgenic mice have shown that the 
CFTR gen can be effectively transferred to epithelial cells of the lung. 
In addition, the mRNA of the gen could be found in bronchiolar and 
alveolar epithelial cells, while the CFTR protein in respiratory epithelial 
cells [110]. Similar works reported the posibility to directly transfer the 
normal CFTR gene to the airway epithelium by the use of a replication-
deficient recombinant adenovirus vector containing the normal CFTR 
cDNA obtained interesting results in-vitro and in-vivo models [111]. 
After treatment, the absence of viral replication or virus-associated 
adverse effects opened a new window in the recovery of the CF lung 
function by gene therapy [112]. Figure 5 represents a scheme of the 
gene delivery by adenovirus. 
In the following years, other methods for gene delivery have been 
explored such as fat capsules, synthetic vectors, nose drops or drizzling 
cells in addition to new aerosol methods using nebulizers. In this 
sense, novel strategies for gene therapy in CF disease are based on 
the discovery of more functional, effective and versatile gene delivery 
systems [113]. However, there is no a specific report of a gene delivery 
system that works properly for all kinds of cell types with no limitations 
or side effects. Some reviews describe in detail the different gene 
delivery systems for germline (like nuclei, egg cells, embryonic stem 
cells, pronuclear, microinjection and sperm cells) and somatic cells by 
the use of: 
• Viral systems: such as retroviral, adenoviral, adeno-
associated vectors, helper-dependent adenoviral systems, hybrid 
adenoviral systems, herpes simplex, pox virus, lentivirus, Epstein–Barr 
virus.
• Non-viral DNA based systems: 
o	Physical: naked DNA, DNA bombardant, electroporation, 
hydrodynamic, ultrasound, magnetofection.
o	Chemical: cationic lipids, different cationic polymers, lipid 
polymers.
The selection of the adequate carrier will be restricted to the 
cell type, the target organ and the treatment duration [114,115]. 
Retroviral vectors are advantageous since they are integrating the 
selected recombinant genes by transduction. Particularly, lentivirus are 
preferred because of they are very stable vectors and able to transfect 
dividing and non-dividing cells by integrating the virus shell directly 
to the nucleus membrane of the cells. Besides, the main problem of 
lentivirus vectors are associated to the lack of surface proteins in the 
capsid for the recognition of respiratory ephitelium receptors [116], 
Also quiescent cells are refractory to the vector because of G0 state in 
where the reverse transcription is blocked [117].
Alternatively, Sendai virus (SeV) originated from mouse 
parainfluenza virus type 1, were explored as potential therapeutic 
vectors. Among the advantages of Sendai vector is a cytoplasm RNA 
expression without the requirement of chromosomal integration, and 
also displaying high transfection efficiency in epithelial cells due to the 
sialic acid and cholesterol receptors [118]. 
Among the viral vector systems, adenoviruses were the first choice 
of candidates for CF gene therapy since the target is the respiratory 
epithelium. However, adenoviruses are strong inducers of immune 
response and also low transduction efficiency which are limiting the 
therapeutic use [116]. Adeno-associated viral are an alternative vectors 
because of extensive gene transfer and expression in non-human 
epithelia and lack of strong immune response [117]. Besides, the main 
limitation of Adeno-associated vectors is related to the large size of 
the CFTR cassette to be inserted in viral capsid. Other viral vectors 
were reported for cystic fibrosis therapy but most of them are unstable 
showing inactive recombinant forms, or very low infectivity.
Overall, the most viral vector systems are made to transfect CFTR-
deficient cells which require repetitive administrations and causing 
both cellular and humoral responses concomitantly with the decrease 
of gene expression [118]. However, the main concern about gene 
Nutrient Frequency to check nutrients levels
At diagnosis Annual Other
Vitamin A x x -
Vitamin D x x -
Vitamin E x x -
Vitamin K x - Hemoptysis or hematemesis cases; liver disease
Essential fatty acids - - Infants
Calcium - - Patients older than 8 years (risk cases)
Iron x x Poor appetite and fatigue
Zinc - - Recommended 6 months supplementation and check changes in growth
Sodium - - Patients exposed to heat stress or dehydration
Protein stores X x Nutritional failure
Beta carotene - - Under criteria of the physician
Table 3. Nutrients to be monitored for establish the nutritional status of CF patients (modified from Borowitz et al., 2002).
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therapy is related to the safety. Viral vectors, particularly retrovirus, 
can elicit from mild acute inflammation to strong immune response 
that can compromise life. In addition, recombination events of the 
vector with potential wild-type viruses present in the patient can trigger 
unpredictable consequences [110].
Regarding to the non-viral gene therapies, up today the transfection 
strategies are very limited with poor efficiencies.
Conclusions
The cystic fibrosis transmembrane regulator mutations comprise 
a complex pathology involving many signaling pathways and organs. 
Present therapies depend of case and they are determined not only by 
the mutations but also physiological and nutritional conditions of the 
patients. Up today, the therapeutic procedures are palliatives trying 
to keep standard levels of life quality based on combination of strict 
medication and nutritional diets. Nanotechnology in these aspects 
can provide novel platforms to treat and prevent the physiological 
consequences of the CF pathology. Particularly, if the pathology can be 
diagnosed in the patients during the early stages and the gene therapy 
proceeds by restoring CFTR activity in immune cells can prevent the 
lung pathology as well as other diseases before overlooked, like diabetes, 
where the role of CFTR mutations also has a role. Gene delivery seems 
to be a strategic area to be considered for the development of novel CF 
therapeutic agents based on the recent contributions of biotechnology 
and nanotechnologies.
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